490 related items for PubMed ID: 19776092
1. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW, GA/minocycline study investigators.
Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
[Abstract] [Full Text] [Related]
2. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G, Filippi M, Wolinsky JS.
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[Abstract] [Full Text] [Related]
3. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[Abstract] [Full Text] [Related]
4. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M, 9006 Study Group.
Neurology; 2007 Mar 20; 68(12):939-44. PubMed ID: 17372130
[Abstract] [Full Text] [Related]
5. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators.
N Engl J Med; 2012 Sep 20; 367(12):1087-97. PubMed ID: 22992072
[Abstract] [Full Text] [Related]
6. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N, Filippi M, Hawkins C, 9011 study group.
J Neurol Sci; 2008 Mar 15; 266(1-2):44-50. PubMed ID: 17897678
[Abstract] [Full Text] [Related]
7. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
Clin Ther; 2008 Jun 15; 30(6):1102-12. PubMed ID: 18640466
[Abstract] [Full Text] [Related]
8. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.
Kornek B, Bernert G, Balassy C, Geldner J, Prayer D, Feucht M.
Neuropediatrics; 2003 Jun 15; 34(3):120-6. PubMed ID: 12910434
[Abstract] [Full Text] [Related]
9. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.
Rovaris M, Comi G, Rocca MA, Valsasina P, Ladkani D, Pieri E, Weiss S, Shifroni G, Wolinsky JS, Filippi M, European/Canadian Glatiramer Acetate Study Group.
Mult Scler; 2007 May 15; 13(4):502-8. PubMed ID: 17483532
[Abstract] [Full Text] [Related]
10. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL.
Mult Scler; 2008 Jun 15; 14(5):663-70. PubMed ID: 18424479
[Abstract] [Full Text] [Related]
11. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.
Filippi M, Wolinsky JS, Comi G, CORAL Study Group.
Lancet Neurol; 2006 Mar 15; 5(3):213-20. PubMed ID: 16488376
[Abstract] [Full Text] [Related]
12. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M, PreCISe study group.
Lancet; 2009 Oct 31; 374(9700):1503-11. PubMed ID: 19815268
[Abstract] [Full Text] [Related]
13. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.
Mult Scler; 2010 Apr 31; 16(4):450-4. PubMed ID: 20150398
[Abstract] [Full Text] [Related]
14. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
Arch Neurol; 2008 Feb 31; 65(2):199-204. PubMed ID: 18071030
[Abstract] [Full Text] [Related]
15. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis.
De Stefano N, Filippi M, Confavreux C, Vermersch P, Simu M, Sindic C, Hupperts R, Bajenaru O, Edan G, Grimaldi L, Marginean I, Medaer R, Orefice G, Pascu I, Pelletier J, Sanders E, Scarpini E, Mancardi GL.
Mult Scler; 2009 Feb 31; 15(2):238-43. PubMed ID: 18987103
[Abstract] [Full Text] [Related]
16. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP, Rovaris M, Comi G, Filippi M.
Neurology; 2009 Nov 10; 73(19):1538-42. PubMed ID: 19794123
[Abstract] [Full Text] [Related]
17. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T, BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G.
Lancet Neurol; 2009 Oct 10; 8(10):889-97. PubMed ID: 19729344
[Abstract] [Full Text] [Related]
18. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
Massacesi L, Parigi A, Barilaro A, Repice AM, Pellicanò G, Konze A, Siracusa G, Taiuti R, Amaducci L.
Arch Neurol; 2005 Dec 10; 62(12):1843-7. PubMed ID: 16344342
[Abstract] [Full Text] [Related]
19. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, Laquinimod in Relapsing MS Study Group.
Neurology; 2005 Mar 22; 64(6):987-91. PubMed ID: 15781813
[Abstract] [Full Text] [Related]
20. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B.
Rev Neurol (Paris); 2008 Nov 22; 164(11):917-26. PubMed ID: 18790510
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
